D-0120-2018 Class I Terminated

Recalled by Amneal Pharmaceuticals Of New York, LLC — Brookhaven, NY

FDA drug recall D-0120-2018 was initiated by Amneal Pharmaceuticals Of New York, LLC on Aug 3, 2017 and is designated Class I. Reason for recall: Defective Delivery System: the dropper measurement markings may be reversed, shifted or missing. The recall status is terminated (terminated Sep 7, 2022). Affected quantity: 136376 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 27, 2017
Initiation Date
Aug 3, 2017
Termination Date
Sep 7, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
136376 bottles

Product description

Lorazepam Oral Concentrate, USP, 2 mg/mL, 30 mL bottle, Rx only, Manufactured by: Amneal Pharmaceuticals Branchburg, NJ 08876. Distributed by: Amneal Pharmaceuticals, Glasgow, KY 42141. NDC 65162-687-84

Reason for recall

Defective Delivery System: the dropper measurement markings may be reversed, shifted or missing.

Distribution pattern

Nationwide

Code information

Lot 06876016A, 06876017A, 06876018A, Exp 08/2018; 06876019A, 06876020A, 06876021A, 06876022A, Exp 09/2018; 06876023A, Exp 11/2018; 06876024A, 06876025A, Exp 12/2018; 06877001A, 06877002A, Exp 02/2019; 06877003A, Exp 03/2019.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0120-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0120-2018. Report a data issue: hello@regdatalab.com.